ACTRIMS 2023

ACTRIMS 2023: RRMS treatment may ‘give patients a better choice’

New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeuticsā€™ novel oral treatment candidateĀ for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was found to safely reduce brain lesions and prevent disability progression in…

ACTRIMS 2023: TG aims to make Briumvi accessible to patients

Briumvi (ublituximab-xiiy) recently became the third anti-CD20 monoclonal antibody to be approved by the U.S. Food and Drug Administration (FDA) as a treatment for relapsing forms of multiple sclerosis (MS). TG Therapeutics, the therapy’s developer, is now aiming to make Briumvi the most accessible therapy in its…

ACTRIMS 2023: CNM-Au8 bound for Phase 3 testing after positive data

Treatment with the experimental oral suspension therapy CNM-Au8 led to improvements in measures of vision, cognitive and motor function, and brain health for people with multiple sclerosis (MS), according to data from the proof-of-concept VISIONARY-MS trial. Bolstered by these positive results,Ā Clene Nanomedicine is planning to launch a…

ACTRIMS 2023: Catching up with Can Do MS

Multiple Sclerosis News Today talks to Kathy Costello, chief operating officer of Can Do MS, at the ACTRIMS Forum 2023 about some of the initiatives and projects coming up for the nonprofit organization. Kathy discusses upcoming initiatives and in-person community programs, including a half-day program taking place at the Consortium…